Nektar Therapeutics NKTR Current ratio

Current ratio at other companies

AmgenAMGN

1.4×+0.1×

Regeneron PharmaceuticalsREGN

3.3×-1.3×

ImmunityBio, Inc.IBRX

6.7×+4.4×

Apogee Therapeutics, Inc.APGE

32.6×+16.8×

Artiva Biotherapeutics, Inc.ARTV

24.2×+10.3×

CTO

Citius Oncology, Inc.CTOR

0.5×+0.1×

FAQ

What is Nektar Therapeutics's current ratio?

Nektar Therapeutics (NKTR) reported current ratio of 10.2× in Q1 2026.

How has Nektar Therapeutics's current ratio changed year-over-year?

Nektar Therapeutics's current ratio increased by 214.9% year-over-year, from 3.2× to 10.2×.

What is the long-term trend for Nektar Therapeutics's current ratio?

Over 5 years (2020 to 2025), Nektar Therapeutics's current ratio has grown at a -12.7% compound annual growth rate (CAGR), from 9.8× to 5×.

What does current ratio mean?

Current assets divided by current liabilities at the quarter end. Measures the company's ability to cover near-term obligations with near-term assets.